Company Overview and News

 
QGEN / QIAGEN N.V. 20-F

2018-03-06 sec.gov
Document UNITED STATES
Upvote Downvote

 
QGEN / QIAGEN N.V. IRANNOTICE

2018-03-06 sec.gov
Document
Upvote Downvote

 
QGEN / QIAGEN N.V. / FRANKLIN RESOURCES INC - 3G/A (Passive Investment)

2018-02-07 sec.gov
qiag17a4.htm - Generated by SEC Publisher for SEC Filing                 CUSIP NO. N72482123                    13G                               Page 1 of 13                                                                                        UNITED STATES                                                               SECURITIES AND EXCHANGE COMMISSION                                                                           Washington, D.
Upvote Downvote

 
QGEN / QIAGEN N.V. / FRANKLIN RESOURCES INC - 3G/A (Passive Investment)

2018-02-07 sec.gov
qiag17a4.htm - Generated by SEC Publisher for SEC Filing                 CUSIP NO. N72482123                    13G                               Page 1 of 13                                                                                        UNITED STATES                                                               SECURITIES AND EXCHANGE COMMISSION                                                                           Washington, D.
Upvote Downvote

 
QGEN / QIAGEN N.V. 6-K (Current Report of Foreign Issuer)

2018-02-03 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________ FORM 6-K   __________________________________   Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2017 Commission File Number 0-28564  __________________________________ QIAGEN N.V. (Translation of registrant’s name into English)  __________________________________ Hulsterweg 82 5
Upvote Downvote

 
QGEN / QIAGEN N.V. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-01-30 fintel.io
QIAGEN N.V. (NYSE:QGEN) has 223 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 162,486,480 shares. Largest shareholders include BlackRock Inc., Franklin Resources Inc, Primecap Management Co/ca/, Deutsche Bank Ag\, Massachusetts Financial Services Co /ma/, Norges Bank, Vanguard Group Inc, Johnston Asset Management Corp, DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main, and Manning & Napier Advisors Llc.
Upvote Downvote

 
QGEN / QIAGEN N.V. / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-30 sec.gov
nl0012169213_012918.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 6) QIAGEN NV -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) BYXS688 -------------------------------------------------------- (SEDOL Number) December 31, 2017 -------------------------------------------------------- (Date
Upvote Downvote

 
QGEN / QIAGEN N.V. / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-30 sec.gov
nl0012169213_012918.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 6) QIAGEN NV -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) BYXS688 -------------------------------------------------------- (SEDOL Number) December 31, 2017 -------------------------------------------------------- (Date
Upvote Downvote

 
QGEN / QIAGEN N.V. FORM 25

2018-01-08 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 _________________________________ FORM 25 _________________________________ NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 0-28564 QIAGEN N.V. The Nasdaq Global Select Market (Exact name of registrant as specified in its charter, and name of Exchange where security is listed and/or registered) Hulsterweg 82 5912 PL Venlo Th
Upvote Downvote

 
QGEN / QIAGEN N.V. QGEN NYSE CERTIFICATION

2018-01-03 sec.gov
Benjamin Sawyer Head of Corporate Actions New York Stock Exchange 11 Wall Street, 14th Floor New York, NY 10005 T +1 212 656 5614 Benjamin.Sawyer@theice.com January 3, 2018 Chief, Information Technology Securities and Exchange Commission Division of Corporate Finance 100 F Street, NE MS 3040 Washington, DC 20549 To whom it may concern: The New York Stock Exchange certifies its approval for listing and registration of the Common Shares, nominal value EUR 0.
Upvote Downvote

 
QGEN / QIAGEN N.V. 6-K (Current Report of Foreign Issuer)

2017-12-26 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549  __________________________________ FORM 6-K   __________________________________ Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month period ended December 31, 2017 Commission File Number 0-28564   __________________________________ QIAGEN N.V. __________________________________   Hulsterweg 82 5912 PL Venlo The Netherlands ______________________
Upvote Downvote

 
QGEN / QIAGEN N.V. 8-A12B

2017-12-20 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549  __________________________________ FORM 8-A  __________________________________ FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 __________________________________ QIAGEN N.V. __________________________________ (Exact name of registrant as specified in its charter) The Netherlands __________________________________ (State or other jurisdiction
Upvote Downvote

 
QGEN / QIAGEN N.V. 6-K (Current Report of Foreign Issuer)

2017-12-12 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549  __________________________________ FORM 6-K   __________________________________ Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month ended December 31, 2017 Commission File Number 0-28564   __________________________________ QIAGEN N.V. __________________________________   Hulsterweg 82 5912 PL Venlo The Netherlands _____________________________
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: N72482107